Team

Dr. Mike Zack is a pioneering physician-scientist and entrepreneur at the forefront of AI-driven precision medicine and multi-omics technologies. With over a decade of specialized experience, he co-founded and currently leads PGxAI, an advanced pharmacogenetics platform leveraging artificial intelligence to optimize drug therapies individually based on comprehensive biological data.

His distinguished career includes over 130 peer-reviewed publications, positioning him in the top 1% of globally cited scientists (Elsevier), with an H-index of 43 and over 43,000 citations. His research has significantly impacted pharmacogenomics, personalized medicine, and AI-driven healthcare, shaping international clinical practices and therapeutic standards.

At PGxAI, Dr. Zack spearheaded the launch of innovative AI models integrating genetic, proteomic, transcriptomic, metabolomic, and clinical data. This multi-dimensional approach enables unprecedented precision in medication selection and dosage, improving therapeutic effectiveness and patient safety.

Under his leadership, PGxAI rapidly evolved from concept to a thriving enterprise, establishing strategic partnerships with leading global technology and healthcare organizations, including InterSystems, Google, Amazon, and Microsoft. His vision has driven practical applications that enhance clinical decision-making and reduce adverse drug reactions in real-world settings.

As a recognized global healthcare innovator, Dr. Zack frequently engages with executives, investors, policymakers, and academia, advocating for accelerated adoption of AI and personalized medicine solutions worldwide.

Allan Gobbs is a Venture Capitalist and Deeptech Entrepreneur. He is a Co-Founder and Managing Partner at ATEM Capital, a New York-based Life Sciences venture firm (www.atemcap.com). His experience includes a $760 million strategic partnership with Domain Associates, one of the oldest US biotech venture groups, where he made 11 high-profile private investments (5 companies listed on NASDAQ, including Atea Pharmaceuticals which demonstrated 30x cash-on-cash return at IPO valuation, 3 companies sold, including Tobira Therapeutics, which was sold at an unprecedented premium of 19x to its current market cap to Allergan).

Allan is a Founder of GATELEAD — Global Advanced Technology Entrepreneurship and Leadership School. GATELEAD applies a unique personalized competency-based approach combined with project-focused learning and empowers teams driving corporate innovations or building their own breakthrough enterprises in Life Sciences, Medtech/Diagnostics & Healthtech.

Before that Mr. Gobbs was a Vice President at Barclays Capital focusing on Energy & Utilities, Telecoms and High Tech sectors. Mr. Gobbs started off his investment banking career at Dresdner Kleinwort, where he advised on a number of M&A and capital markets transactions worth over $20 billion.

Board Memberships include: Marinus (NASDAQ: MRNS), Tobira (NASDAQ: TBRA, sold to Allergan), Neothetics (NASDAQ: NEOT, sold), OcuNexus, Adastra, NovaDigm, Atea (NASDAQ: AVIR) and Revision Optics (observer), Syndax (NASDAQ: SNDX) (observer), Miramar Labs (observer, sold).

Mr. Gobbs is an official member of the Forbes Business Council, a member of the Private Directors Association (PDA) (previously he was also a member of the National Association of Corporate Directors) and a member of the Review Committee of the National Cancer Institute at NIH.

With a rich background in tech development, Alex has made significant strides at Intel Corporation, where he has served for over 14 years. His role as Product Manager and Architect has been crucial in developing the Intel® Single Event API and managing the post-silicon development of Graphics Drivers for MacOS, in collaboration with Apple. His earlier contributions at Intel include improving performance and usability with the VTune Amplifier XE and leading architectural developments in the Graphics Performance Analyzers. Before Intel, Alex was instrumental in developing surveillance products at Speclab, showcasing his diverse skill set in software and hardware architecture. His innovative approach and leadership in tech development mark him as a key asset to our team.

Danil Stupichev is a trailblazing bioinformatics expert specializing in machine learning–driven oncology solutions and multi-omics data analysis. With over five years of focused experience in next-generation sequencing (NGS) and a background spanning physics, mathematics, biology, and computer science, Danil stands at the cutting edge of personalized medicine.

Throughout his tenure at BostonGene, he spearheaded multiple research and development initiatives, optimizing biomarker discovery pipelines and leading a team of 10 bioinformaticians. Under Danil’s leadership, the team consistently pushed the boundaries of computational biology, achieving zero turnover and elevating junior members to senior roles—all while driving impactful outcomes in biomarker identification and cancer diagnostics.

Currently, at PGxAI, Danil integrates high-throughput genomics and advanced computational methodologies to refine pharmacogenetic platforms, ensuring that medication choices and dosages are tailored to individual genomic profiles. His comprehensive approach—encompassing RNA-seq, scRNA-seq, whole exome sequencing (WES), and multiplex immunofluorescence (MxIF)—has led to high-profile presentations at conferences including AACR, SITC, and USCAP, and has supported transformative clinical studies showcased at ESMO and other global forums.

Danil’s commitment to precision healthcare is fueled by his passion for translating complex datasets into actionable insights. Whether developing proprietary data-analysis tools or authoring standard operating procedures that elevate diagnostic quality, he remains devoted to innovation that directly improves patient outcomes. His blend of technical leadership, scientific rigor, and cross-functional collaboration exemplifies the future of AI-driven, personalized oncology.

Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation.

Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”

Emily received her Ph.D in Molecular Pathology from UCSD in 2002 investigating specificity of metalloproteinases in breast cancer metastasis using phage display libraries. As a postdoctoral fellow she began studying molecular mechanism of tumor suppressor genes and breast cancer metastasis using shotgun proteomics. In 2009, she joined Stony Brook School of Medicine and then joined Columbia University School of Medicine in 2013 as an independent investigator and as the director of proteomics shared resource to support mass spectrometry-based analysis. She has extensive publications on applying proteomics technology to study basic biology and translational biomarker discovery using patient samples. In 2018, she joined Thermo Fisher as the Sr. director of the Precision Medicine Science Center in Cambridge MA.

Dr. Terry Robins is a distinguished leader in the design and execution of global clinical trials, clinical laboratory operations, and the commercialization of innovative diagnostic technologies. With a PhD in Molecular Biology from the University of California, Berkeley, he brings over two decades of senior leadership experience at industry frontrunners such as Abbott, Alere, and Quest Diagnostics.

During his tenure as Senior Director of Clinical Affairs, Infectious Disease at Abbott, Dr. Robins directed large-scale international trials and was instrumental in guiding advanced diagnostic solutions from concept to market. Prior to Abbott, he served as Global Director of Scientific Affairs and Biomarker R&D at Quest Diagnostics, spearheading the development and integration of novel biomarkers across multiple disease areas. His track record also includes driving high-impact R&D initiatives as Vice President at Pathway Diagnostics.

A graduate of the prestigious I-Corps @ NIH Program, Dr. Robins has a proven history of translating cutting-edge science into real-world clinical and commercial success. At PGxAI, he provides strategic advisory in harnessing AI-driven precision medicine, ensuring that next-generation multi-omics platforms seamlessly reach patients and clinicians for improved outcomes worldwide.

Joydeep has over 25 years of experience in engineering, product management, sales, marketing, and M&A in pharmaceutical, medical devices, and payer industries. Joydeep earned an MBA from Northwestern University’s Kellogg School of Management and a Bachelor of Technology Degree in Electrical Engineering from NIT India.

David A. Moser is a dynamic commercial leader at the intersection of digital health, diagnostics, and precision medicine. With a track record of launching new ventures and building high-performing sales organizations, David has propelled revenue growth for cutting-edge companies like GeneDx, imaware, and Deciphex.

Throughout his career, David has excelled at bridging innovation with real-world market needs—negotiating complex sales agreements, orchestrating strategic partnerships, and guiding early-stage tech transformations from concept to commercial success. His deep expertise spans genomics, digital pathology, and at-home testing solutions, enabling him to deliver scalable go-to-market strategies and impactful collaborations with hospitals, CROs, and leading biotech firms.

Passionate about advancing healthcare through actionable diagnostics and AI-driven insights, David’s leadership style centers on forging genuine relationships and delivering measurable results. His ability to connect the dots between diverse stakeholders—clinicians, innovators, and payers—embodies his commitment to making top-tier diagnostic and genomic solutions accessible to patients worldwide.